Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: OPK stock price vs VTRS: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at VTRS's multiple
Needs VTRS P/S.
Implied fair value · at OPK's multiple
Needs OPK P/S.
Metric by metric
Live quote
Price unavailable
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: OPK FY 2025 (ended Dec 31, 2025) · VTRS FY 2025 (ended Dec 31, 2025).
Trendline
Six fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
OPKO Health, Inc. · implied price per share
Bear
-$1.74
Base
-$2.04
Bull
-$2.35
VIATRIS INC. · implied price per share
Bear
-$14.68
Base
-$17.27
Bull
-$19.86
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.54x
0.98x
Net debt / EBITDA
Leverage against operating earnings
-3.43x
560.04x
Cash and equivalents
Liquid reserves on the balance sheet
$368.94M
$1.36B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
AMARIN CORP PLC\UK
OPK vs AMRN
Sarepta Therapeutics, Inc.
OPK vs SRPT
Amphastar Pharmaceuticals, Inc.
OPK vs AMPH
SUPERNUS PHARMACEUTICALS, INC.
OPK vs SUPN
Harmony Biosciences Holdings, Inc.
OPK vs HRMY
PFIZER INC
OPK vs PFE
Organon & Co.
OPK vs OGN
BRISTOL MYERS SQUIBB CO
OPK vs BMY
AbbVie Inc.
OPK vs ABBV
Merck & Co., Inc.
OPK vs MRK
$687.93M
$14.41B
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
